Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma

Shaji K Kumar, Francis K. Buadi, Betsy LaPlant, Alese Halvorson, Nelson Leung, Prashant Kapoor, David M Dingli, Morie Gertz, Ronald S. Go, Peter Leif Bergsagel, Yi Lin, Angela Dispenzieri, Yi Lisa Hwa, Amie Fonder, Miriam Hobbs, Rafael Fonseca, Suzanne R. Hayman, Alexander Keith Stewart, John A. Lust, Joseph R MikhaelWilson Gonsalves, Craig Reeder, Tomas Skacel, S Vincent Rajkumar, Martha Lacy

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Ixazomib is the first oral proteasome inhibitor to enter the clinic. Given the efficacy of bortezomib in combination with cyclophosphamide and dexamethasone, we studied the combination of ixazomib, cyclophosphamide and dexamethasone (ICd) in newly diagnosed multiple myeloma (NDMM) and patients with measurable disease, irrespective of transplant eligibility, were enrolled. The phase 1 was to determine the maximum tolerated dose (MTD) of cyclophosphamide in the combination. Patients received ixazomib 4 mg (days 1, 8, 15), dexamethasone 40 mg (days 1, 8, 15, 22), and cyclophosphamide 300 or 400 mg/m2 days 1, 8, 15, 22; cycles were 28 days. We enrolled 51 patients, 10 in phase 1 and 41 patients in phase 2. The median age was 64.5 years (range: 41–88); 29% had high or intermediate risk FISH. The MTD was 400 mg/m2 of cyclophosphamide weekly. The best confirmed response in all 48 patients included ≥ partial response in 77%, including ≥ VGPR in 35%; 3 patients had a sCR. The response rate for all 48 evaluable patients at 4-cycles was 71%; the median time to response was 1.9 months. Common adverse events included cytopenias, fatigue and GI intolerance. ICd is a convenient, all oral combination that is well tolerated and effective in NDMM.

Original languageEnglish (US)
Article number70
JournalBlood Cancer Journal
Volume8
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

Multiple Myeloma
Cyclophosphamide
Dexamethasone
Maximum Tolerated Dose
Proteasome Inhibitors
ixazomib
Fatigue
Transplants

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. / Kumar, Shaji K; Buadi, Francis K.; LaPlant, Betsy; Halvorson, Alese; Leung, Nelson; Kapoor, Prashant; Dingli, David M; Gertz, Morie; Go, Ronald S.; Bergsagel, Peter Leif; Lin, Yi; Dispenzieri, Angela; Hwa, Yi Lisa; Fonder, Amie; Hobbs, Miriam; Fonseca, Rafael; Hayman, Suzanne R.; Stewart, Alexander Keith; Lust, John A.; Mikhael, Joseph R; Gonsalves, Wilson; Reeder, Craig; Skacel, Tomas; Rajkumar, S Vincent; Lacy, Martha.

In: Blood Cancer Journal, Vol. 8, No. 8, 70, 01.08.2018.

Research output: Contribution to journalArticle

Kumar, Shaji K ; Buadi, Francis K. ; LaPlant, Betsy ; Halvorson, Alese ; Leung, Nelson ; Kapoor, Prashant ; Dingli, David M ; Gertz, Morie ; Go, Ronald S. ; Bergsagel, Peter Leif ; Lin, Yi ; Dispenzieri, Angela ; Hwa, Yi Lisa ; Fonder, Amie ; Hobbs, Miriam ; Fonseca, Rafael ; Hayman, Suzanne R. ; Stewart, Alexander Keith ; Lust, John A. ; Mikhael, Joseph R ; Gonsalves, Wilson ; Reeder, Craig ; Skacel, Tomas ; Rajkumar, S Vincent ; Lacy, Martha. / Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. In: Blood Cancer Journal. 2018 ; Vol. 8, No. 8.
@article{0575161119a14cab80c080019216fc36,
title = "Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma",
abstract = "Ixazomib is the first oral proteasome inhibitor to enter the clinic. Given the efficacy of bortezomib in combination with cyclophosphamide and dexamethasone, we studied the combination of ixazomib, cyclophosphamide and dexamethasone (ICd) in newly diagnosed multiple myeloma (NDMM) and patients with measurable disease, irrespective of transplant eligibility, were enrolled. The phase 1 was to determine the maximum tolerated dose (MTD) of cyclophosphamide in the combination. Patients received ixazomib 4 mg (days 1, 8, 15), dexamethasone 40 mg (days 1, 8, 15, 22), and cyclophosphamide 300 or 400 mg/m2 days 1, 8, 15, 22; cycles were 28 days. We enrolled 51 patients, 10 in phase 1 and 41 patients in phase 2. The median age was 64.5 years (range: 41–88); 29{\%} had high or intermediate risk FISH. The MTD was 400 mg/m2 of cyclophosphamide weekly. The best confirmed response in all 48 patients included ≥ partial response in 77{\%}, including ≥ VGPR in 35{\%}; 3 patients had a sCR. The response rate for all 48 evaluable patients at 4-cycles was 71{\%}; the median time to response was 1.9 months. Common adverse events included cytopenias, fatigue and GI intolerance. ICd is a convenient, all oral combination that is well tolerated and effective in NDMM.",
author = "Kumar, {Shaji K} and Buadi, {Francis K.} and Betsy LaPlant and Alese Halvorson and Nelson Leung and Prashant Kapoor and Dingli, {David M} and Morie Gertz and Go, {Ronald S.} and Bergsagel, {Peter Leif} and Yi Lin and Angela Dispenzieri and Hwa, {Yi Lisa} and Amie Fonder and Miriam Hobbs and Rafael Fonseca and Hayman, {Suzanne R.} and Stewart, {Alexander Keith} and Lust, {John A.} and Mikhael, {Joseph R} and Wilson Gonsalves and Craig Reeder and Tomas Skacel and Rajkumar, {S Vincent} and Martha Lacy",
year = "2018",
month = "8",
day = "1",
doi = "10.1038/s41408-018-0106-3",
language = "English (US)",
volume = "8",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma

AU - Kumar, Shaji K

AU - Buadi, Francis K.

AU - LaPlant, Betsy

AU - Halvorson, Alese

AU - Leung, Nelson

AU - Kapoor, Prashant

AU - Dingli, David M

AU - Gertz, Morie

AU - Go, Ronald S.

AU - Bergsagel, Peter Leif

AU - Lin, Yi

AU - Dispenzieri, Angela

AU - Hwa, Yi Lisa

AU - Fonder, Amie

AU - Hobbs, Miriam

AU - Fonseca, Rafael

AU - Hayman, Suzanne R.

AU - Stewart, Alexander Keith

AU - Lust, John A.

AU - Mikhael, Joseph R

AU - Gonsalves, Wilson

AU - Reeder, Craig

AU - Skacel, Tomas

AU - Rajkumar, S Vincent

AU - Lacy, Martha

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Ixazomib is the first oral proteasome inhibitor to enter the clinic. Given the efficacy of bortezomib in combination with cyclophosphamide and dexamethasone, we studied the combination of ixazomib, cyclophosphamide and dexamethasone (ICd) in newly diagnosed multiple myeloma (NDMM) and patients with measurable disease, irrespective of transplant eligibility, were enrolled. The phase 1 was to determine the maximum tolerated dose (MTD) of cyclophosphamide in the combination. Patients received ixazomib 4 mg (days 1, 8, 15), dexamethasone 40 mg (days 1, 8, 15, 22), and cyclophosphamide 300 or 400 mg/m2 days 1, 8, 15, 22; cycles were 28 days. We enrolled 51 patients, 10 in phase 1 and 41 patients in phase 2. The median age was 64.5 years (range: 41–88); 29% had high or intermediate risk FISH. The MTD was 400 mg/m2 of cyclophosphamide weekly. The best confirmed response in all 48 patients included ≥ partial response in 77%, including ≥ VGPR in 35%; 3 patients had a sCR. The response rate for all 48 evaluable patients at 4-cycles was 71%; the median time to response was 1.9 months. Common adverse events included cytopenias, fatigue and GI intolerance. ICd is a convenient, all oral combination that is well tolerated and effective in NDMM.

AB - Ixazomib is the first oral proteasome inhibitor to enter the clinic. Given the efficacy of bortezomib in combination with cyclophosphamide and dexamethasone, we studied the combination of ixazomib, cyclophosphamide and dexamethasone (ICd) in newly diagnosed multiple myeloma (NDMM) and patients with measurable disease, irrespective of transplant eligibility, were enrolled. The phase 1 was to determine the maximum tolerated dose (MTD) of cyclophosphamide in the combination. Patients received ixazomib 4 mg (days 1, 8, 15), dexamethasone 40 mg (days 1, 8, 15, 22), and cyclophosphamide 300 or 400 mg/m2 days 1, 8, 15, 22; cycles were 28 days. We enrolled 51 patients, 10 in phase 1 and 41 patients in phase 2. The median age was 64.5 years (range: 41–88); 29% had high or intermediate risk FISH. The MTD was 400 mg/m2 of cyclophosphamide weekly. The best confirmed response in all 48 patients included ≥ partial response in 77%, including ≥ VGPR in 35%; 3 patients had a sCR. The response rate for all 48 evaluable patients at 4-cycles was 71%; the median time to response was 1.9 months. Common adverse events included cytopenias, fatigue and GI intolerance. ICd is a convenient, all oral combination that is well tolerated and effective in NDMM.

UR - http://www.scopus.com/inward/record.url?scp=85050740081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050740081&partnerID=8YFLogxK

U2 - 10.1038/s41408-018-0106-3

DO - 10.1038/s41408-018-0106-3

M3 - Article

C2 - 30061664

AN - SCOPUS:85050740081

VL - 8

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 8

M1 - 70

ER -